Avian Influenza Wild Bird Surveillance

The National Avian Influenza Wild Bird (NAIWB) Surveillance Program was expanded in July 2005.  A steering group facilitates collaboration between Australia's states and territories and coordinates the avian influenza wild bird surveillance activities. WHA provides support to the NAIWB Steering Group and collate avian influenza (AI) and avian paramyxovirus (APMV) surveillance data from wild birds sampled across Australia. The Steering Group meets quarterly via teleconference with one annual face to face meeting. 

The NAIWB Surveillance Program activities are conducted Australia-wide, with funding provided by the Australian Government Department of Agriculture and Water Resources and in 2011/12 funding from the Rural Industries Research and Development Corporation (RIRDC) Chicken Meat Program. In-kind support is provided by the jurisdictional agencies, researchers and representative’s institutions.

The Program has two main components: targeted surveillance and general surveillance. Targeted surveillance will continue to focus on sampling from Anseriformes (waterfowl), specifically from locations where there is known mixing with birds from the Charadriiformes (shorebirds) Order and that bring waterfowl into close proximity to poultry and humans. Where possible, surveillance will continue in locations previously sampled to obtain longitudinal data. General surveillance focuses on exclusion of AIV and APMVs from mass mortality and morbidity events in wild birds around Australia and the Australian Antarctic Territory. 

Between July 2005 and June 2016, over 94,000 wild birds have been tested for influenza viruses. To date, no highly pathogenic AI viruses have been identified in Australian wild birds. However, there is evidence of infection with low pathogenic AI viruses (LPAI). 

For more information please contact admin@wildlifehealthaustralia.com.au 


Objectives of the 2017 NAIWB Surveillance Program

1.
Detect avian influenza and avian paramyxovirus-1 (APMV-1) in wild birds,
2. Contribute to a better understanding of AI and APMV-1 phylogeny and gene flow of subtypes, ecology and epidemiology to support industry and human and wildlife health strategic risk assessment and management,
3.  Maintain national AI & APMV-1 laboratory diagnostic capacity and capability,
4.  Sharing and communication of data nationally and globally,
5.  Contribute to One Health through regular communication of AI and APMV-1 virus data to the Department of Health with specific analysis of wild bird AIVs for likelihood of infection and transmission in humans, and
6. Exclude AIV, specifically H5 and H7, as well as APMVs, specifically virulent strains, in mass mortality events in wild birds.



Useful References: